31 min listen
Fighting COVID-19: Regeneron's George Yancopoulos
FromLeadership Next
ratings:
Length:
27 minutes
Released:
Mar 20, 2020
Format:
Podcast episode
Description
Business, when it’s at its best, can solve very big problems. And today Leadership Next is talking about a very big problem - COVID-19.
George Yancopoulos is the President and Chief Scientific Officer of Regeneron. His company announced this week it has developed a promising drug to fight coronavirus, and will begin human trials by early summer.
Yancopoulos details the innovative approach Regeneron used to create the drug - an approach that led to an effective therapy for Ebola.
He also explains that a Regeneron drug aimed at patients with rheumatoid arthritis is currently being used to treat some of the worst symptoms of COVID-19. The treatment is still in a trial phase but, if successful, could potentially keep severely ill patients off of ventilators.
Leadership Next host Alan Murray told Yancopoulos, “This is the most encouraging conversation I’ve had in quite awhile.”
George Yancopoulos is the President and Chief Scientific Officer of Regeneron. His company announced this week it has developed a promising drug to fight coronavirus, and will begin human trials by early summer.
Yancopoulos details the innovative approach Regeneron used to create the drug - an approach that led to an effective therapy for Ebola.
He also explains that a Regeneron drug aimed at patients with rheumatoid arthritis is currently being used to treat some of the worst symptoms of COVID-19. The treatment is still in a trial phase but, if successful, could potentially keep severely ill patients off of ventilators.
Leadership Next host Alan Murray told Yancopoulos, “This is the most encouraging conversation I’ve had in quite awhile.”
Released:
Mar 20, 2020
Format:
Podcast episode
Titles in the series (100)
Airbnb's Brian Chesky: 'We are a better company now': The COVID-19 crisis has brought the travel industry to its knees, but Airbnb's CEO sees good things ahead for his company. Here's why. by Leadership Next